View Clinical Trial (Medical Research Study)

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury - NCT00407745-46250(Clinical Trial 156184)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Indianapolis
State:  
IN
Zip Code: 46250
Conditions: Neuralgia - Spinal Cord Injuries
Purpose: The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.
Study summary:
Criteria: Inclusion Criteria: - Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and after removal of benign tumors (except meningioma and fibromas) - Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6 months - Pain score at least 4 in 4 of 7 days prior to receive treatment. Exclusion Criteria: - Pregabalin use in the last 60 days, prior intolerance to pregabalin - Creatinine clearance <60 mL/min. - White blood cell count <2500/mm3; neutrophil count <1500/mm3; platelet count <100 x 103/ mm3. - Abuse of drugs or alcohol - Unstable medial conditions - Clinically significant abnormal electrocardiogram (ECG). - Presence of severe pain associated with conditions other than spinal cord injury that could confound the assessment or self-evaluation of pain due to spinal cord injury.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 17, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.